HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous bone marrow transplantation in a child with acute promyelocytic leukemia in second remission.

Abstract
Acute myeloid leukemia (AML) comprises 15%-20% of childhood acute leukemia cases. The long-term disease free survival (DFS) in childhood AML is poor with standard chemotherapy alone. Early intensive chemotherapy is generally regarded to be necessary for achieving high complete remission (CR) rates. Recent experience has shown that incorporation of early intensification with high-dose melphalan conditioning and autologous bone marrow transplantation (BMT) during the first remission significantly improves long-term DFS in children with AML. In this article, we report the use of autologous BMT for treatment of a three-and-half year old child with acute promyelocytic leukemia (APL or M3) in second remission. The patient was conditioned with high-dose melphalan of 180 mg/kg prior to bone marrow reinfusion. A total of 4.0 x 10(7)/kg mononuclear cells and 1.07 x 10(5)/kg granulomonocytic colony forming units (CFU-GM) were infused. Haematopoietic stem cells were enriched by almost 20-fold after the separation and cryopreservation procedures. Haematological recovery was achieved four-and-a-half weeks post-BMT. She has remained in complete remission 18 months after transplantation. Our experience in this patient indicates that this procedure can be used in second remission and it may provide a better alternative for the management of childhood AML in Singapore.
AuthorsT C Quah, A E Yeoh, L Sun
JournalSingapore medical journal (Singapore Med J) Vol. 38 Issue 8 Pg. 344-6 (Aug 1997) ISSN: 0037-5675 [Print] India
PMID9364889 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Melphalan
Topics
  • Antineoplastic Agents, Alkylating (administration & dosage)
  • Bone Marrow Transplantation (methods)
  • Disease-Free Survival
  • Female
  • Humans
  • Infant
  • Leukemia, Promyelocytic, Acute (therapy)
  • Melphalan (administration & dosage)
  • Remission Induction
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: